Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone interferes with the parasite’s mitochondrial electron transport chain, halting energy production, while proguanil is converted to cycloguanil, which blocks the dihydrofolate reductase enzyme needed for DNA synthesis. The combined effect kills the malaria parasite more efficiently than either agent alone.

The specific dose and duration of Malarone therapy are determined by the prescribing clinician based on the indication, patient weight, age, and regional resistance patterns. Patients should follow the prescriber’s instructions and complete the full course as directed.

Safety data for Malarone in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with older agents such as chloroquine, Malarone offers a broader spectrum against resistant Plasmodium strains and a convenient once‑daily dosing schedule. Doxycycline is another alternative for prophylaxis, but it requires daily dosing and can cause photosensitivity, whereas Malarone is generally well tolerated.

Malarone tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Malarone is taken orally with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, taken daily throughout the stay, and continued for 7 days after leaving. Treatment regimens differ and are prescribed by a clinician.

Serious adverse events, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, hemolysis in patients with G6PD deficiency, and severe neutropenia. Prompt medical attention is required if symptoms like rash, jaundice, dark urine, or unexplained fever develop.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Patients with severe renal impairment should avoid use unless specifically advised by a physician, and those with G6PD deficiency should be monitored closely due to hemolysis risk.